140 related articles for article (PubMed ID: 23335529)
1. Is there a correlation between molecular markers and response to neoadjuvant chemoradiotherapy in locally advanced squamous cell esophageal cancer?
Arsenijevic T; Micev M; Nikolic V; Gavrilovic D; Radulovic S; Pesko P
J BUON; 2012; 17(4):706-11. PubMed ID: 23335529
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
3. [ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
Sobajima J; Haga N; Kumamoto K; Ishibashi K; Ishida H
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2394-6. PubMed ID: 21224584
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma.
Perisanidis C; Perisanidis B; Wrba F; Brandstetter A; El Gazzar S; Papadogeorgakis N; Seemann R; Ewers R; Kyzas PA; Filipits M
J Oral Pathol Med; 2012 Jan; 41(1):40-6. PubMed ID: 21883486
[TBL] [Abstract][Full Text] [Related]
6. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer.
Brabender J; Metzger R; Vallböhmer D; Ling F; Neiss S; Bollschweiler E; Schneider PM; Hölscher AH; Grimminger PP
Surgery; 2012 Feb; 151(2):306-12. PubMed ID: 21982526
[TBL] [Abstract][Full Text] [Related]
7. Expression and alteration of p53 and p21(waf1/cip1) influence the sensitivity of chemoradiation therapy for esophageal cancer.
Shimoyama S; Konishi T; Kawahara M; Aoki F; Harada N; Shimizu S; Murakami T; Kaminishi M
Hepatogastroenterology; 1998; 45(23):1497-504. PubMed ID: 9840093
[TBL] [Abstract][Full Text] [Related]
8. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.
Yamashita H; Murakami N; Asari T; Okuma K; Ohtomo K; Nakagawa K
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1165-72. PubMed ID: 19101092
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma.
Gotoh M; Takiuchi H; Kawabe S; Ohta S; Kii T; Kuwakado S; Katsu K
Jpn J Clin Oncol; 2007 Sep; 37(9):652-7. PubMed ID: 17940077
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
[TBL] [Abstract][Full Text] [Related]
11. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
12. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
Akutsu Y; Hanari N; Yusup G; Komatsu-Akimoto A; Ikeda N; Mori M; Yoneyama Y; Endo S; Miyazawa Y; Matsubara H
Ann Surg Oncol; 2011 Oct; 18(10):2946-51. PubMed ID: 21437756
[TBL] [Abstract][Full Text] [Related]
13. [Chemoradiotherapy followed by surgery in treatment of locally advanced esophageal carcinoma: a phase II trial].
Fu JH; Rong TH; Li XD; Hu Y; Ou W; Hu YH; Li Q
Ai Zheng; 2004 Nov; 23(11 Suppl):1473-6. PubMed ID: 15566661
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma.
Samejima R; Kitajima Y; Yunotani S; Miyazaki K
Anticancer Res; 1999; 19(6C):5515-21. PubMed ID: 10697609
[TBL] [Abstract][Full Text] [Related]
15. Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer.
Suzuki T; Sadahiro S; Tanaka A; Okada K; Kamata H; Kamijo A; Murayama C; Akiba T; Kawada S
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1232-8. PubMed ID: 23158058
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
[TBL] [Abstract][Full Text] [Related]
17. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus.
Heeren PA; Kloppenberg FW; Hollema H; Mulder NH; Nap RE; Plukker JT
Anticancer Res; 2004; 24(4):2579-83. PubMed ID: 15330218
[TBL] [Abstract][Full Text] [Related]
18. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
[TBL] [Abstract][Full Text] [Related]
19. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
[TBL] [Abstract][Full Text] [Related]
20. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
Narumiya K; Metzger R; Bollschweiler E; Alakus H; Brabender J; Drebber U; Hölscher AH; Warnecke-Eberz U
Pharmacogenomics; 2011 Feb; 12(2):205-14. PubMed ID: 21332314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
